Molly Tilley is a Nephrology physician. OpenAlex indexes 10 publications with 230 citations (h-index 8).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1501 NE Medical Center Dr
Bend, OR 977016051
Telephone
541-382-2811Provider last certified this registry record 29 Mar 2021.
Industry payments
2 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Boehringer Ingelheim Pharmaceuticals, Inc.Program year20231 payment
- Travere Therapeutics, Inc.Program year20211 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Blood & clotting
67.4%Iron, parenteral preparations66.9%Ferric carboxymaltose100%Part B, office-administered≥18 patientsSolutions for parenteral nutrition0.3%Calcium Acetate100%Part D≥22 patients+ 2 more classes in this area
Cardiovascular
13.1%Angiotensin receptor blocker (ARB)2.3%Losartan Potassium83%Irbesartan6%Olmesartan Medoxomil5%Telmisartan3%Candesartan Cilexetil3%Part D<11 patientsStatin1.9%Atorvastatin Calcium59%Rosuvastatin Calcium22%Pravastatin Sodium12%Simvastatin7%Part D≥75 patients+ 14 more classes in this area
Musculoskeletal
8.6%RANK Ligand Inhibitor7.8%Denosumab100%Part B, office-administered≥27 patientsXanthine oxidase inhibitor0.5%Allopurinol100%Part D≥38 patients+ 2 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Dysnatremias and Survival in Adult Burn Patients: A Retrospective Analysis
American Journal of Nephrology
2013 - Anaphylactoid Reaction during First Hemofiltration with a PUREMA® Polysulfone Membrane
The International Journal of Artificial Organs
2013 - Anaphylactoid reaction during first hemofiltration with a PUREMA (registered trademark) polysulfone membrane2013
Similar KOLs
Other experts from the same institution or the same specialty.
Giuseppe Remuzzi
Mario Negri Institute for Pharmacological Research
Marcello Tonelli
University of Calgary
Johan Ärnlöv
Dalarna University
Juan Jesús Carrero
Danderyds sjukhus
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”